Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RGX-104 |
| Trade Name | |
| Synonyms | RGX104|RGX 104 |
| Drug Descriptions |
RGX-104 activates liver-X nuclear hormone receptor (LXR), resulting in ApoE expression and enhancement of antitumor immunity (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B001, PMID: 32448508). |
| DrugClasses | |
| CAS Registry Number | 610318-03-1 |
| NCIT ID | C131910 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Durvalumab + Nab-paclitaxel + Pemetrexed Disodium + RGX-104 | Carboplatin Durvalumab Nab-paclitaxel Pemetrexed Disodium RGX-104 | 0 | 1 |
| Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | Carboplatin Pembrolizumab Pemetrexed Disodium RGX-104 | 0 | 1 |
| Docetaxel + RGX-104 | Docetaxel RGX-104 | 0 | 0 |
| Ipilimumab + RGX-104 | Ipilimumab RGX-104 | 0 | 1 |
| Nivolumab + RGX-104 | Nivolumab RGX-104 | 0 | 1 |
| RGX-104 | RGX-104 | 0 | 1 |